@article{7bceafad1aed4430bff9eabf7332c833,
title = "脂質異常症治療の最前線",
keywords = "Cholesterol(血液), Dicarboxylic Acids(治療的利用), 危険因子, *脂質異常症(合併症,診断,薬物療法), モノクローナル抗体(治療的利用), 脂肪酸(治療的利用), 動脈硬化症(病因,診断,予防), Evidence-Based Medicine, 診療ガイドライン, Ezetimibe(治療的利用), siRNA(治療的利用), Evolocumab(治療的利用), Inclisiran(治療的利用), Evinacumab(治療的利用), Bempedoic Acid(治療的利用), 久山町, ヒト",
author = "塚本 和久",
year = "2024",
month = sep,
language = "Japanese",
volume = "113",
pages = "1794--1801",
journal = "Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine",
issn = "0021-5384",
publisher = "Japanese Society of Internal Medicine",
number = "9",
}